Jiangsu Lianhuan Pharmaceutical Dirección

Dirección controles de criterios 4/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Ben Niu

Chief Executive Officer (CEO)

CN¥709.8k

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	1.5yrs
Participación del CEO	n/a
Permanencia media de la dirección	3.4yrs
Promedio de permanencia en la Junta Directiva	4.7yrs

Actualizaciones recientes de la dirección

Recent updates

Jiangsu Lianhuan Pharmaceutical's (SHSE:600513) Profits Appear To Have Quality Issues

Sep 11

We Think That There Are More Issues For Jiangsu Lianhuan Pharmaceutical (SHSE:600513) Than Just Sluggish Earnings

Mar 12

CEO

Ben Niu (42 yo)

1.5yrs

Permanencia

CN¥709,800

Compensación

Mr. Ben Niu serves as Chief Engineer at Jiangsu Lianhuan Pharmaceutical Co., Ltd. since May 22, 2020 and serves as its General Manager since March 8, 2023.

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Ben Niu	Chief Engineer & GM	1.5yrs	CN¥709.80k	sin datos
Heping Pan	Vice Chairman	3.4yrs	CN¥731.20k	sin datos
Wen Tao Huang	Secretary of the Board of Directors	6.3yrs	CN¥657.20k	sin datos
Zhou Jun	Deputy General Manager	no data	CN¥732.10k	sin datos
Yi Shen	Deputy General Manager	no data	CN¥674.60k	sin datos
Yong Jun Zhu	Deputy General Manager	no data	CN¥666.50k	sin datos

3.4yrs

Permanencia media

55yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 600513 se considera experimentado (3.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Heping Pan	Vice Chairman	3.4yrs	CN¥731.20k	sin datos
Chunlai Xia	Director	8.4yrs	sin datos	sin datos
Wenge Wu	Chairman	10.3yrs	CN¥829.20k	sin datos
Guangji Wang	Director	6.1yrs	sin datos	sin datos
Zhen Hua Qian	Director	6.3yrs	CN¥760.30k	sin datos
Ying Chen	Independent Director	5.1yrs	CN¥80.00k	sin datos
Bin Zhang	Independent Director	4.3yrs	CN¥80.00k	sin datos
Jing Zhang	Employee Supervisor	3.4yrs	sin datos	sin datos
Baochang Yu	Chairman of the Supervisory Board	3.4yrs	sin datos	sin datos
Chunyuan Wang	Supervisor	3.4yrs	sin datos	sin datos

4.7yrs

Permanencia media

53yo

Promedio de edad

Junta con experiencia: La junta directiva de 600513 se considera experimentada (4.6 años de antigüedad promedio).

Jiangsu Lianhuan Pharmaceutical Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Jiangsu Lianhuan Pharmaceutical Co., Ltd., Annual General Meeting, Mar 28, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Jiangsu Lianhuan Pharmaceutical's (SHSE:600513) Profits Appear To Have Quality Issues

New major risk - Financial position

Second quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.10 in 2Q 2023)

Jiangsu Lianhuan Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Dividend of CN¥0.15 announced

First quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.11 in 1Q 2023)

Jiangsu Lianhuan Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

We Think That There Are More Issues For Jiangsu Lianhuan Pharmaceutical (SHSE:600513) Than Just Sluggish Earnings

Jiangsu Lianhuan Pharmaceutical Co., Ltd., Annual General Meeting, Mar 28, 2024

Full year 2023 earnings released: EPS: CN¥0.47 (vs CN¥0.49 in FY 2022)

New major risk - Share price stability

Investor sentiment deteriorates as stock falls 20%

Jiangsu Lianhuan Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 06, 2024

New minor risk - Share price stability

Investor sentiment improves as stock rises 23%

Third quarter 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.12 in 3Q 2022)

Jiangsu Lianhuan Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 31, 2023

Second quarter 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.12 in 2Q 2022)

Jiangsu Lianhuan Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 26, 2023

First quarter 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.11 in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥0.49 (vs CN¥0.41 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.11 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.10 in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.09 in 1Q 2021)

Less than half of directors are independent

Third quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.12 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.10 (vs CN¥0.089 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.07 in 1Q 2020)

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.36 (vs CN¥0.28 in FY 2019)

Jiangsu Lianhuan Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day low: CN¥8.73

Investor sentiment deteriorated over the past week

New 90-day low: CN¥9.96

New 90-day low: CN¥9.99

Third quarter earnings released

Jiangsu Lianhuan Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 30, 2020

Earnings released

Jiangsu Lianhuan Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 22, 2020

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad